Anika Therapeutics (NASDAQ: ANIK)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Anika Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Anika Therapeutics Company Info
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
News & Analysis
A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.
Better-than-expected Q2 earnings results spurred investors' interest in the small biotech.
Wall Street wasn't nearly as optimistic as it should have been about the biotech's second quarter.
Find out which of these companies took the biggest hit.
Shares dropped after the company reported data from a late-stage trial. Here's what investors need to know.
On the hunt for a biotech bargain? Our contributors think you should give these stocks a closer look.
Three Motley Fool analysts tell investors which biotechnology stocks are on their wish list this month.
Anika (ANIK) won FDA approval for Monovisc, but sales will have to be strong to justify its recent move higher.
Valuation
Earnings Transcripts
ANIK earnings call for the period ending September 30, 2021.
ANIK earnings call for the period ending June 30, 2021.
ANIK earnings call for the period ending March 31, 2021.
ANIK earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.